On Tuesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: E I Du Pont De Nemours And (NYSE:DD), LyondellBasell Industries (NYSE:LYB), Freeport-McMoRan (NYSE:FCX), Organovo Holdings (NYSEMKT:ONVO)
E I Du Pont De Nemours And Co (NYSE:DD) received the 2015 Bio Business Award for Breakthrough Bio-Based Technology Platform at the World Bio Markets Conference awards ceremony in Amsterdam. A global leader in the Bioeconomy, DuPont was recognized for DuPont(TM) Sorona(R) biopolymer, a sustainably sourced, high-performance fiber that contains 37 percent renewable plant-based ingredients, and uses 30 percent less energy and releases 63 percent fewer greenhouse gas emissions contrast to ordinaryly used nylon 6.
E I Du Pont De Nemours And Co (NYSE:DD)’s shares picked down -3.10%, and closed at $74.68. The stock volatility for the week is 2.03%, while for the month remained 4.37%. The company holds consensus target price of $75.24.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 3.89 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 28.60% and Annual EPS growth for the past 5 years is considered as 15.30%.
The mean recommendation of analysts for this stock is 2.80. (Where 1=Buy, 5=Sale).
E I Du Pont De Nemours And Co (DD) works as a science and technology based corporation worldwide. The corporation’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.
LyondellBasell Industries NV (NYSE:LYB) decreased -3.06%, and closed at $82.66, hitting new 52-week low of $-3.06. The stock has price to sale ratio of 0.86, however, price to book ratio is 4.91. With recent decline, the year-to-date (YTD) performance reflected a 2.56% incline below last year. During the past month the stock lose -8.09%, bringing three-month performance to 9.34% and six-month performance to -25.92%. The mean recommendation of analysts for this stock is 2.30 (where 1=Buy, 5=Sale).
LyondellBasell Industries NV (LYB) works as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers. The corporation operates in five segments: Olefins and PolyolefinsAmericas; Olefins and PolyolefinsEurope, Asia, International; Intermediates and Derivatives; Refining; and Technology.
Freeport-McMoRan Inc (NYSE:FCX) decreased -3.06%, and closed at $17.42. The company holds the market capitalization of $18.69B. For the last twelve months, the stock was able to keep return on equity at -6.40%, while return on assets at -2.10%, in response to its return on investment at -0.40%. Its 20-day moving average decreased -14.10%, below 50-day moving average of -12.80%, below 200-day moving average of -39.40% from the latest market price of $17.42. The mean recommendation of analysts for this stock is 2.40. (where 1=Buy, 5=Sale).
Freeport-McMoRan Inc (FCX) a natural resource company, engages in the acquisition of mineral assets, and oil and natural gas resources. It primarily explores for copper, GOLD, molybdenum, cobalt, silver, and other metals, as well as oil and gas.
Organovo Holdings Inc (NYSEMKT:ONVO) a three-dimensional biology corporation focused on delivering breakthrough 3D bioprinting technology, uncovered that the March 5th presentation given by President and CEO Keith Murphy is now accessible for on-demand viewing at VirtualInvestorConferences.com.
Organovo Holdings Inc (NYSEMKT:ONVO) fell -3.05%, and closed at $4.45, hitting new 52-week low of $-3.05. The stock has the beta value of -0.18, and its volatility for the week is 10.01%, while for the month it is 6.32%. The company has the market capitalization of $369.31M. The company holds the book value per share of 0.60, whereas cash per share is 0.62. Price to book ratio remained 7.42, while price to sale ratio is 895.23. Analysts mean recommendation for the stock is said to be 3.00 (where 1=Buy, 5=sale).
Organovo Holdings Inc (ONVO) a development-stage corporation focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
